We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Venous Support System Improves CABG Outcomes

By HospiMedica International staff writers
Posted on 02 Dec 2021
A novel device could lead to increased longevity and durability of saphenous vein grafts (SVG) during coronary artery bypass graft (CABG) surgery, according to a new study.

The venous external support (VEST) system, under development by Vascular Graft Solutions (VGS; Tel Aviv, Israel) is a fine, kink-resistant cobalt-chromium wire mesh that is placed over a SVG to prevent non-uniform graft dilatation post-implantation, mitigate formation of disturbed blood flow patterns, and prevent subsequent development of intimal hyperplasia. More...
Two models are available (VEST and VEST 2.0); VEST 2.0 is more pliable, as it is braided of thinner wires, and can be cut intraoperatively by the surgeon to fit desired SVG length.

The results of a recent randomized, controlled, clinical trial comparing VEST supported and non-supported vein grafts up to five years post CABG demonstrated that VEST can mitigate pathological remodeling of SVGs, significantly reduce intimal hyperplasia and lumen irregularities, and improves blood flow hemodynamics. The study was presented as a late-breaking clinical trial during the virtual American Heart Association Scientific Sessions, broadcast from Dallas (TX, USA) during November 2021.

“Vein grafts have a limited durability; about half of them will be closed ten years after CABG. We need to find a solution to improve outcomes of surgery and prevent complications and repeated procedures,” said lead author and study presenter John Puskas, MD, chair of cardiovascular surgery at Mount Sinai Morningside (NY, NY, USA). “Among patients with complete intravascular ultrasound data, VEST was associated with statistically reduced intimal hyperplasia.”

SVGs are the most frequently used bypass conduits in CABG surgery. But saphenous veins normally experience low pressure in the leg; the higher-pressure environment of the coronary arteries can cause intimal hyperplasia, which promotes atherosclerosis and may lead to eventual closure. SVG failure rates range from 35% to 50% (five to ten years following CABG surgery), doubling the risk for re-intervention.

Related Links:
Vascular Graft Solutions


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Absorbable Monofilament Mesh
Phasix Mesh
New
Electrically Operated Patient Lifter
SVL 205
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.